Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 1, Issue 2, 2005, Pages 101-109

  Kawasaki, Ernest S ^a   Player, Audrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Drug delivery; Nanomedicine; Nanoparticles; Nanotechnology; Quantum dots

Indexed keywords

CANCER THERAPY; DRUG DELIVERY; NANOMEDICINE; NANOPARTICLES;

DIAGNOSIS; DISEASES; DRUG THERAPY; MEDICAL APPLICATIONS; MEDICAL IMAGING; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; ONCOLOGY; SEMICONDUCTOR QUANTUM DOTS;

TUMORS;

ACETYLSALICYLIC ACID; CANCER VACCINE; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; QUANTUM DOT;

ACCURACY; ANALYTIC METHOD; CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; GENE THERAPY; HUMAN; IMAGING; NANOTECHNOLOGY; PROTEIN INTERACTION; PROTEOMICS; QUALITY OF LIFE; REVIEW; SCIENCE; VACCINATION;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG THERAPY; GENE THERAPY; HUMANS; NANOMEDICINE; NEOPLASMS; ROBOTICS;

EID: 33646245291     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2005.03.002     Document Type: Review

References (90)

1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
2. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
3. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431 (2004) 931-945
4. Player A., Barrett J.C., and Kawasaki E.S. Laser capture microdissection, microarrays and the precise definition of a cancer cell. Expert Rev Mol Diagn 4 (2004) 831-840
5. Joachim C., Emerich D.F., Wu X., Liu H., Liu J., Haley K.N., et al. To be nano or not to be nano?. Nat Mater 4 (2005) 107-109
6. Alivisatos A.P. Semiconductor clustors, nanocrystals, and quantum dots. Science 271 (1996) 933-937
7. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol 22 (2004) 47-52
8. Bruchez Jr. M., Moronne M., Gin P., Weiss S., and Alivisatos A.P. Semiconductor nanocrystals as fluorescent biological labels. Science 281 (1998) 2013-2016
9. Smith A.M., Gao X., and Nie S. Quantum dot nanocrystals for in vivo molecular and cellular imaging. Photochem Photobiol 80 (2004) 377-385
10. Anderson S.A., Glod J., Arbab A.S., Noel M., Ashari P., Fine H.A., et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105 (2005) 420-425
11. Gupta A.K., and Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26 (2005) 3995-4021
12. Harisinghani M.G., and Weissleder R. Sensitive, noninvasive detection of lymph node metastases. Public Libr Sci Med 1 (2004) e66
13. Hutten A., Sudfeld D., Ennen I., Reiss G., Hachmann W., Heinzmann U., et al. New magnetic nanoparticles for biotechnology. J Biotechnol 112 (2004) 47-63
14. Lian W., Litherland S.A., Badrane H., Tan W., Wu D., Baker H.V., et al. Ultrasensitive detection of biomolecules with fluorescent dye-doped nanoparticles. Anal Biochem 334 (2004) 135-144
15. Wu X., Liu H., Liu J., Haley K.N., Treadway J.A., Larson J.P., et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21 (2003) 41-46
16. Smith A.M., and Nie S. Chemical analysis and cellular imaging with quantum dots. Analyst 129 (2004) 672-677
17. Jaiswal J.K., Goldman E.R., Mattoussi H., and Simon S.M. Use of quantum dots for live cell imaging. Nat Methods 1 (2004) 73-78
18. Jaiswal J.K., Mattoussi H., Mauro J.M., and Simon S.M. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 21 (2003) 47-51
19. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307 (2005) 538-544
20. Han M., Gao X., Su J.Z., and Nie S. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol 19 (2001) 631-635
21. Mattheakis L.C., Dias J.M., Choi Y.J., Gong J., Bruchez M.P., Liu J., et al. Optical coding of mammalian cells using semiconductor quantum dots. Anal Biochem 327 (2004) 200-208
22. Jain R.K., and Stroh M. Zooming in and out with quantum dots. Nat Biotechnol 22 (2004) 959-960
23. Jiang W., Papa E., Fischer H., Mardyani S., and Chan W.C. Semiconductor quantum dots as contrast agents for whole animal imaging. Trends Biotechnol 22 (2004) 607-609
24. Larson D.R., Zipfel W.R., Williams R.M., Clark S.W., Bruchez M.P., Wise F.W., et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 300 (2003) 1434-1436
25. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., and Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99 (2002) 12617-12621
26. Voura E.B., Jaiswal J.K., Mattoussi H., and Simon S.M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10 (2004) 993-998
27. Jakub J.W., Pendas S., and Reintgen D.S. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist 8 (2003) 59-68
28. Kim S., Lim Y.T., Soltesz E.G., De Grand A.M., Lee J., Nakayama A., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22 (2004) 93-97
29. Gao X., Cui Y., Levenson R.M., Chung L.W., and Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22 (2004) 969-976
30. Ghoroghchian P.P., Frail P.R., Susumu K., Blessington D., Brannan A.K., Bates F.S., et al. Near-infrared-emissive polymersomes: self-assembled soft matter for in vivo optical imaging. Proc Natl Acad Sci U S A 102 (2005) 2922-2927
31. Petri-Fink A., Chastellain M., Juillerat-Jeanneret L., Ferrari A., and Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26 (2005) 2685-2694
32. Lotze M.T., Wang E., Marincola F.M., Hanna N., Bugelski P.J., Burns C.A., et al. Workshop on cancer biometrics. Identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 28 (2005) 79-119
33. Posadas E.M., Simpkins F., Liotta L.A., MacDonald C., and Kohn E.C. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?. Ann Oncol 16 (2005) 16-22
34. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102 (2005) 2273-2276
35. Keating C.D. Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc Natl Acad Sci U S A 102 (2005) 2263-2264
36. Nam J.M., Thaxton C.S., and Mirkin C.A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301 (2003) 1884-1886
37. Liotta L.A., Ferrari M., and Petricoin E. Clinical proteomics: written in blood. Nature 425 (2003) 905
38. Sahoo S.K., and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 8 (2003) 1112-1120
39. Vasir J.K., Reddy M.K., and Labhasetwar V. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 1 (2005) 47-64
40. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284 (2004) 109-122
41. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113 (2004) 151-170
42. Rabinow B.E. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3 (2004) 785-796
43. Horn D., and Rieger J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew Chem Int Ed 40 (2001) 4330-4361
44. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 (2005) 145-160
45. Wissing S.A., Kayser O., and Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56 (2004) 1257-1272
46. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99 (2004) 259-269
47. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109 (2004) 759-767
48. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56 (2004) 1649-1659
49. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
50. Yu W., Pirollo K.F., Yu B., Rait A., Xiang L., Huang W., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32 (2004) e48
51. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., and Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64 (2004) 7668-7672
52. Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64 (2004) 2853-2857
53. Gillies E.R., and Frechet J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10 (2005) 35-43
54. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32 (2004) e149
55. Whitesides G.M. The "right" size in nanobiotechnology. Nat Biotechnol 21 (2003) 1161-1165
56. Sun Q., Wang Q., Rao B.K., and Jena P. Electronic structure and bonding of Au on a SiO2 cluster: a nanobullet for tumors. Phys Rev Lett 93 (2004) 186803/1-186803/4
57. Hood L., Heath J.R., Phelps M.E., and Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 306 (2004) 640-643
58. Hood L., and Perlmutter R.M. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 22 (2004) 1215-1217
59. Kamb A. Opinion: what's wrong with our cancer models?. Nat Rev Drug Discov 4 (2005) 161-165
60. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
61. Groner B., Hartmann C., and Wels W. Therapeutic antibodies. Curr Mol Med 4 (2004) 539-547
62. von Eschenbach A.C. A vision for the National Cancer Program in the United States. Nat Rev Cancer 4 (2004) 820-828
63. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3 (2004) 301-317
64. Brooijmans N., and Kuntz I.D. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 32 (2003) 335-373
65. Card G.L., Blasdel L., England B.P., Zhang C., Suzuki Y., Gillette S., et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23 (2005) 201-207
66. Erlanson D.A., Wells J.A., and Braisted A.C. Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct 33 (2004) 199-223
67. Lipinski C., and Hopkins A. Navigating chemical space for biology and medicine. Nature 432 (2004) 855-861
68. Rees D.C., Congreve M., Murray C.W., and Carr R. Fragment-based lead discovery. Nat Rev Drug Discov 3 (2004) 660-672
69. Shoichet B.K. Virtual screening of chemical libraries. Nature 432 (2004) 862-865
70. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1 (2002) 493-502
71. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
72. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A (2005)
73. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 102 (2005) 1992-1997
74. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
75. Crooke S.T. Antisense strategies. Curr Mol Med 4 (2004) 465-487
76. Jhaveri M.S., Rait A.S., Chung K.N., Trepel J.B., and Chang E.H. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3 (2004) 1505-1512
77. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3 (2004) 318-329
78. Downward J. Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene 23 (2004) 8376-8383
79. Fuchs U., Damm-Welk C., and Borkhardt A. Silencing of disease-related genes by small interfering RNAs. Curr Mol Med 4 (2004) 507-517
80. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 4 (2004) 401-411
81. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
82. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
83. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 (2004) 3148-3154
84. Stauffer P.R., and Goldberg S.N. Introduction: thermal ablation therapy. Int J Hyperthermia 20 (2004) 671-677
85. Brongersma M.L. Nanoscale photonics: nanoshells: gifts in a gold wrapper. Nat Mater 2 (2003) 296-297
86. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 100 (2003) 13549-13554
87. O'Neal D.P., Hirsch L.R., Halas N.J., Payne J.D., and West J.L. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 209 (2004) 171-176
88. Alper J. US NCI launches nanotechnology plan. Nat Biotechnol 22 (2004) 1335-1336
89. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
90. Blagosklonny M.V. How cancer could be cured by 2015. Cell Cycle 4 (2005)